 This research paper discusses the development of a novel intranasally-delivered transferisome nanovessical, QRTFS, formulation for quercidin, QR, a nitrocytical compound used to protect the brain from oxidative stress-induced neurodegeneration. The researchers found that the optimized QRTFS formulation had a higher rate of absorption than the QR solution, as well as a more sustained release pattern and increased permeability through the nasal mucosa. Furthermore, they observed that the GNPs produced by the QRTFS formulation accumulated in the brains of treated animals, suggesting that this formulation could be used to deliver QER to the brain. This article was authored by Muhammad H. Alkami, random Muhammad Zaki, Omar Al-Saidan, and others.